Background: This phase I, dose-finding study driven the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), pharmacokinetics, and antitumour activity of PX-866, a phosphatidylinositol 3-kinase inhibitor, coupled with docetaxel in patients with incurable solid tumours. continued to be on Gja1 research for 180 times, including 8 who taken care of disease control on single-agent… Continue reading Background: This phase I, dose-finding study driven the safety, maximum tolerated